Company Apricus Biosciences Inc Nasdaq
Equities
US03832V1098
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
May. 16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
May. 14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Director of Finance/CFO | 52 | 18-12-31 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gopal Krishna
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 66 | - | |
Anthony Marciano
IRC | Investor Relations Contact | - | 17-07-31 |
Lucas Pilipski
PRN | Corporate Officer/Principal | - | 20-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 21-08-31 | |
Richard Pascoe
CHM | Chairman | 60 | 13-02-28 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 18-12-31 |
Brian Lian
BRD | Director/Board Member | 58 | 18-12-31 |
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,859,767 | 2,825,530 ( 98.80 %) | 0 | 98.80 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
REGNUM CORP. 98.82% | 22,680,000 | 98.82% | 725,760 $ |
Company contact information
![address Apricus Biosciences Inc](https://cdn.zonebourse.com/static/address/6617806.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- SEEL Stock
- Stock
- Company Apricus Biosciences Inc